Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report

Pulmonary large cell neuroendocrine carcinoma (LCNEC), which accounts for approximately 1% of all lung cancers, is a rare and highly aggressive malignancy with a poor prognosis. Therefore, it is important to devise an effective treatment strategy. In the treatment of locally advanced complex LCNEC,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian Xu, Qi Feng, Yong Chen, Xiu-lan Liu, Ou Jiang
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bb031ed25ef141748682e81cd0711210
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb031ed25ef141748682e81cd0711210
record_format	dspace
spelling	oai:doaj.org-article:bb031ed25ef141748682e81cd07112102021-11-06T00:03:24ZComplete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report1473-230010.1177/03000605211055387https://doaj.org/article/bb031ed25ef141748682e81cd07112102021-11-01T00:00:00Zhttps://doi.org/10.1177/03000605211055387https://doaj.org/toc/1473-2300Pulmonary large cell neuroendocrine carcinoma (LCNEC), which accounts for approximately 1% of all lung cancers, is a rare and highly aggressive malignancy with a poor prognosis. Therefore, it is important to devise an effective treatment strategy. In the treatment of locally advanced complex LCNEC, it is unique to first administer radiotherapy combined with albumin-bound paclitaxel plus carboplatin, followed by durvalumab for immune maintenance treatment after concurrent radiotherapy and chemotherapy to achieve complete remission. We report a 54-year-old man who smoked and who felt chest tightness for 2 weeks and was diagnosed as having combined pulmonary LCNEC. For patients with locally advanced pulmonary LCNEC, chemoradiotherapy increases overall survival. After surgical resection and chemoradiotherapy, our patient achieved complete remission. Durvalumab was then started to consolidate the treatment. After six courses of immune maintenance therapy, the patient developed grade 2 immune-related pneumonitis and took prednisone orally until the symptoms resolved, and then reached complete remission again. The patient achieved complete remission, which was a challenge with this rare carcinoma, through albumin-bound paclitaxel plus platinum-based chemotherapy combined with radiotherapy and durvalumab for immune maintenance therapy. This approach may provide a treatment option for locally advanced combined pulmonary LCNEC.Jian XuQi FengYong ChenXiu-lan LiuOu JiangSAGE PublishingarticleMedicine (General)R5-920ENJournal of International Medical Research, Vol 49 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jian Xu Qi Feng Yong Chen Xiu-lan Liu Ou Jiang Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
description	Pulmonary large cell neuroendocrine carcinoma (LCNEC), which accounts for approximately 1% of all lung cancers, is a rare and highly aggressive malignancy with a poor prognosis. Therefore, it is important to devise an effective treatment strategy. In the treatment of locally advanced complex LCNEC, it is unique to first administer radiotherapy combined with albumin-bound paclitaxel plus carboplatin, followed by durvalumab for immune maintenance treatment after concurrent radiotherapy and chemotherapy to achieve complete remission. We report a 54-year-old man who smoked and who felt chest tightness for 2 weeks and was diagnosed as having combined pulmonary LCNEC. For patients with locally advanced pulmonary LCNEC, chemoradiotherapy increases overall survival. After surgical resection and chemoradiotherapy, our patient achieved complete remission. Durvalumab was then started to consolidate the treatment. After six courses of immune maintenance therapy, the patient developed grade 2 immune-related pneumonitis and took prednisone orally until the symptoms resolved, and then reached complete remission again. The patient achieved complete remission, which was a challenge with this rare carcinoma, through albumin-bound paclitaxel plus platinum-based chemotherapy combined with radiotherapy and durvalumab for immune maintenance therapy. This approach may provide a treatment option for locally advanced combined pulmonary LCNEC.
format	article
author	Jian Xu Qi Feng Yong Chen Xiu-lan Liu Ou Jiang
author_facet	Jian Xu Qi Feng Yong Chen Xiu-lan Liu Ou Jiang
author_sort	Jian Xu
title	Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
title_short	Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
title_full	Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
title_fullStr	Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
title_full_unstemmed	Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
title_sort	complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/bb031ed25ef141748682e81cd0711210
work_keys_str_mv	AT jianxu completeremissionofcombinedpulmonarylargecellneuroendocrinecarcinomaacasereport AT qifeng completeremissionofcombinedpulmonarylargecellneuroendocrinecarcinomaacasereport AT yongchen completeremissionofcombinedpulmonarylargecellneuroendocrinecarcinomaacasereport AT xiulanliu completeremissionofcombinedpulmonarylargecellneuroendocrinecarcinomaacasereport AT oujiang completeremissionofcombinedpulmonarylargecellneuroendocrinecarcinomaacasereport
_version_	1718444004724441088

Complete remission of combined pulmonary large cell neuroendocrine carcinoma: a case report

Ejemplares similares